Emerging concepts for the treatment of hepatitis delta
Emerging concepts for the treatment of hepatitis delta
复制标题
DOI：
10.1016/j.coviro.2017.04.004
复制
发表时间：
2017-06-01
影响因子：
5.9
通讯作者：
Glenn, Jeffrey S.
中科院分区：
文献类型：
--
作者：
Elazar, Menashe;Glenn, Jeffrey S.
丁型肝炎病毒（HDV）引起最严重的人类病毒性肝炎，并与肝硬化、肝功能失代偿和肝癌的高风险相关。干扰素是迄今为止唯一证明有效的药物，尽管反应率很低，并且与显著的副作用相关。对相关分子病毒学的更好理解导致了新的候选靶点的确定。随着几种新药进入临床开发，未来的治疗选择正在迅速发展，包括进入抑制剂myrcludexb、抑制HBV表面抗原分泌的核酸聚合物REP2139-Ca、靶向病毒组装的法尼基转移酶抑制剂lonafarnib和耐受性更好的干扰素干扰素lambda。
Hepatitis delta virus (HDV) causes the most severe form of human viral hepatitis and is associated with a higher risk of cirrhosis, liver decompensation and liver cancer. Interferon alpha is the only agent that has demonstrated efficacy to date, although response rates are low and it is associated with significant side effects. A better understanding of the relevant molecular virology has resulted in the identification of new candidate targets. Future therapeutic options are rapidly evolving as several new agents have entered clinical development, including the entry inhibitor myrcludex-B, the nucleic acid polymer REP2139-Ca inhibiting HBV surface antigen secretion, the farnesyltransferase inhibitor lonafarnib that targets virus assembly, and a better tolerated interferon interferon lambda.